Despite Recent Setbacks At Pfizer, R&D Chief Is Optimistic About R&D Innovation
This article was originally published in The Pink Sheet Daily
Executive Summary
Mikael Dolsten cites Pfizer's latest efforts to be more efficient, improve R&D productivity, and implement precision medicine as key to its rebound.